Category Pharmaceuticals
Dalhousie’s Case Diversification: Anti-Oppression and Race (Part 3)
Lynette Reid describes the work done at Dalhousie to diversify the case-based learning (CBL) curriculum in the medical program.
Dalhousie’s Case Diversification: Anti-oppression and Race (Part 2)
Lynette Reid describes the work done at Dalhousie to diversify the case-based learning curriculum in the medical program.
Dalhousie’s Case Diversification: An Anti-oppressive Approach to Race
Lynette Reid describes the work done at Dalhousie University to diversify the case-based learning curriculum in the medical program.
CASGEVY: Rethinking Drug Costs Through the Lens of Public Access
Maria Klimenko considers the extent to which the price of innovative treatments like CASGEVY, a type of gene therapy, should reflect not just the cost of development, but also their broader societal impact — and the public healthcare system’s ability to provide equitable access.
Prove AI Can’t Care First
Jean-Christophe Bélisle-Pipon argues that defaulting to AI in health settings could do more harm than good.
Impact Ethics 